Table 1.
Characteristics of PWID and/or are on OAT at Treatment Initiation, British Columbia Hepatitis Testers Cohort
| Covariates | Off‐OAT/RIDU | Off‐OAT/PIDU | Off‐OAT/NIDU | On‐OAT/IDU | On‐OAT/NIDU |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| n | 390 | 598 | 3,515 | 609 | 171 |
| Birth cohort | |||||
| <1945 | 10 (1.7) | 207 (5.9) | 2 (0.3) | 1 (0.6) | |
| 1945‐1964 | 236 (60.5) | 419 (70.1) | 2,833 (80.6) | 313 (51.4) | 102 (59.6) |
| 1965‐1974 | 97 (24.9) | 130 (21.8) | 315 (9) | 170 (27.9) | 40 (23.4) |
| ≥1975 | 57 (14.6) | 39 (6.5) | 160 (4.6) | 124 (20.3) | 28 (16.4) |
| Age | |||||
| <50 | 131 (33.6) | 142 (23.8) | 366 (10.4) | 247 (40.6) | 57 (33.3) |
| 50‐59 | 179 (45.9) | 293 (49) | 1,403 (39.9) | 273 (44.9) | 85 (49.8) |
| ≥60 | 80 (20.5) | 163 (27.2) | 1,746 (49.7) | 89 (14.6) | 29 (17) |
| Sex | |||||
| Female | 117 (30) | 213 (35.6) | 1,167 (33.2) | 219 (35.9) | 45 (26.3) |
| Male | 273 (70) | 385 (64.3) | 2,348 (66.8) | 390 (64.1) | 126 (73.7) |
| Ethnicity | |||||
| White | 376 (96.4) | 579 (96.8) | 3,202 (91.1) | 596 (97.9) | 158 (92.4) |
| Others | 14 (3.6) | 19 (3.2) | 313 (8.9) | 13 (2.1) | 13 (7.6) |
| Treatment duration | |||||
| <8 weeks | 4 (1.1) | 5 (0.9) | 12 (0.3) | 6 (1) | |
| 8 weeks | 74 (19) | 84 (14.1) | 695 (19.8) | 93 (15.3) | 26 (15.2) |
| 12 weeks | 267 (68.4) | 430 (71.9) | 2,265 (64.4) | 446 (73.2) | 127 (74.3) |
| >12‐<24 weeks | 10 (2.6) | 4 (0.7) | 54 (1.5) | 9 (1.4) | 1 (0.6) |
| 24 weeks | 35 (9) | 75 (12.5) | 489 (13.9) | 55 (9) | 17 (9.9) |
| Previous treatment | |||||
| No | 333 (85.3) | 470 (78.6) | 2,762 (78.6) | 524 (86) | 150 (87.7) |
| Yes | 57 (14.6) | 128 (21.4) | 753 (21.4) | 85 (14) | 21 (12.3) |
| HCV RNA viral load (IU/mL)* | |||||
| <124,677 (Q1) | 98 (25.1) | 160 (26.7) | 850 (24.1) | 164 (26.9) | 43 (25.2) |
| 124,677‐670,049 (Q2) | 114 (29.2) | 126 (21.1) | 866 (24.6) | 160 (26.3) | 48 (28.1) |
| 670,049‐2,212,170 (Q3) | 81 (20.8) | 149 (24.9) | 920 (26.1) | 122 (20) | 44 (25.8) |
| ≥2,212,170 (Q4) | 97 (24.9) | 158 (26.4) | 860 (24.5) | 163 (26.8) | 36 (21.1) |
| Missing | 5 (0.8) | 19 (0.5) | |||
| Diabetes* | |||||
| No | 347 (89) | 541 (90.5) | 3,179 (90.4) | 557 (91.5) | 169 (98.9) |
| Yes | 43 (11) | 57 (9.5) | 336 (9.6) | 52 (8.5) | 2 (1.2) |
| Cirrhosis* | |||||
| No | 351 (90) | 533 (89.1) | 3,137 (89.2) | 567 (93.1) | 165 (96.5) |
| Yes | 39 (10) | 65 (10.8) | 378 (10.8) | 42 (6.9) | 6 (3.5) |
| Decompensated cirrhosis | |||||
| No | 371 (95.2) | 564 (94.3) | 3,324 (94.5) | 580 (95.2) | 169 (98.9) |
| Yes | 19 (4.9) | 34 (5.7) | 191 (5.5) | 29 (4.8) | 2 (1.2) |
| HBV | |||||
| No | 338 (86.6) | 526 (87.9) | 3,351 (95.3) | 524 (86.1) | 160 (93.6) |
| Yes | 52 (13.3) | 72 (12.1) | 164 (4.7) | 85 (13.9) | 11 (6.4) |
| HIV | |||||
| No | 299 (76.6) | 507 (84.8) | 3,336 (94.9) | 446 (73.2) | 149 (87.1) |
| Yes | 91 (23.4) | 91 (15.2) | 179 (5.1) | 163 (26.8) | 22 (12.9) |
| Problematic alcohol use | |||||
| Recent | 154 (39.5) | 65 (10.8) | 151 (4.3) | 102 (16.7) | 8 (4.7) |
| Past | 98 (25.1) | 267 (44.7) | 339 (9.6) | 211 (34.7) | 28 (16.4) |
| None | 138 (35.4) | 266 (44.5) | 3,025 (86.1) | 296 (48.6) | 135 (79) |
| Mental illness | |||||
| No | 132 (33.8) | 232 (38.8) | 2,872 (81.8) | 248 (40.8) | 136 (79.6) |
| Yes | 258 (66.1) | 366 (61.2) | 643 (18.3) | 361 (59.2) | 35 (20.5) |
| Elixhauser comorbidity index | |||||
| No (0) | 46 (11.8) | 49 (8.2) | 1,705 (48.5) | 71 (11.7) | 119 (69.6) |
| Yes (≥1) | 344 (88.2) | 549 (91.8) | 1,810 (51.5) | 538 (88.3) | 52 (30.4) |
| Material deprivation | |||||
| Q1 (most privileged) | 70 (17.9) | 80 (13.3) | 513 (14.6) | 120 (19.7) | 25 (14.6) |
| Q2 | 45 (11.6) | 84 (14.1) | 667 (18.9) | 77 (12.6) | 21 (12.3) |
| Q3 | 56 (14.4) | 106 (17.7) | 760 (21.7) | 97 (15.9) | 31 (18.1) |
| Q4 | 91 (23.4) | 159 (26.6) | 779 (22.1) | 108 (17.8) | 43 (25.2) |
| Q5 (most deprived) | 127 (32.5) | 164 (27.4) | 760 (21.6) | 192 (31.6) | 48 (28) |
| Unknown | 1 (0.3) | 5 (0.8) | 36 (1) | 15 (2.5) | 3 (1.8) |
| Social deprivation | |||||
| Q1 (most privileged) | 25 (6.4) | 54 (9) | 400 (11.4) | 39 (6.4) | 23 (13.5) |
| Q2 | 37 (9.5) | 70 (11.7) | 473 (13.4) | 58 (9.5) | 12 (7) |
| Q3 | 34 (8.8) | 92 (15.4) | 698 (19.9) | 71 (11.6) | 23 (13.5) |
| Q4 | 71 (18.2) | 133 (22.2) | 845 (24.1) | 94 (15.4) | 34 (19.9) |
| Q5 (most deprived) | 222 (57) | 244 (40.8) | 1,063 (30.2) | 332 (54.5) | 76 (44.4) |
| Unknown | 1 (0.3) | 5 (0.8) | 36 (1) | 15 (2.5) | 3 (1.8) |
| Treatment year | |||||
| 2010‐2014 | 5 (1.3) | 6 (1) | 76 (2.2) | 4 (0.7) | |
| 2015‐2017 | 385 (98.7) | 592 (99) | 3,439 (97.8) | 605 (99.3) | 171 (100) |
| Treatment type | |||||
| LDV/SOF | 227 (58.2) | 375 (62.7) | 2,368 (67.4) | 351 (57.7) | 92 (53.8) |
| LDV/SOF + RBV | 3 (0.8) | 6 (1) | 52 (1.5) | 4 (0.7) | 4 (2.3) |
| SOF/VEL | 145 (37.2) | 185 (30.9) | 959 (27.3) | 217 (35.7) | 68 (39.7) |
| SOF/VEL + RBV | 15 (3.9) | 32 (5.3) | 136 (3.9) | 37 (6.1) | 7 (4.1) |
| Genotype | |||||
| Genotype 1 | 267 (68.5) | 447 (74.7) | 2,710 (77.1) | 427 (70.1) | 122 (71.3) |
| Genotype 2 | 20 (5.2) | 39 (6.6) | 265 (7.6) | 23 (3.8) | 4 (2.4) |
| Genotype 3 | 91 (23.3) | 92 (15.4) | 371 (10.6) | 135 (22.2) | 41 (24) |
| Other/unknown | 12 (3.1) | 20 (3.4) | 169 (4.8) | 24 (4) | 4 (2.3) |
*
Assessed at the last treatment prescription.
Abbreviation: Q, quartile.